Content
Search
Navigation
Sitemap

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Cell therapy companies
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
all Gene therapy companies
Freeline Therapeutics
AGTC
SwanBio Therapeutics
Purespring Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
OMass Therapeutics
Kesmalea Therapeutics

09.11.22

Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors

Operating News
Cell therapy
Resolution Therapeutics

07.11.22

Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for induced pluripotent stem cell (iPSC)-derived macrophage cell therapies

Operating News
Cell therapy
Resolution Therapeutics

20.07.22

Resolution Therapeutics Appoints Bill Symonds to its Board of Directors

Operating News
Cell therapy
Resolution Therapeutics

30.06.22

Resolution Therapeutics Appoints Dr Amol Ketkar as Chief Development Officer

Operating News
Cell therapy
Resolution Therapeutics

05.04.22

Resolution Therapeutics and panCELLa Inc announce a Research Evaluation & Option Agreement to develop iPSC-derived macrophage cell therapy for inflammatory organ disease

Cell therapy
Resolution Therapeutics

05.04.22

Resolution Therapeutics Announces a £10m Extended Series A Financing from Syncona Ltd

Operating News
Cell therapy
Resolution Therapeutics

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and Insights
Investors
Contact

Copyright © Syncona 2023
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

GBX 144.77

Change: +7.37 (+5.37%)

Search

Search